Vanguard, Morgan Stanley, & Blackrock Are Buying This Tiny Biotech.
Reason #1: Three of the World’s Largest Investment Firms Agree…
Let’s face it, there are many reasons to love biotech companies. Especially ones that can create patented lifesaving dr-ugs with minimal side-effects and protected against future competition.
If you didn’t know, patent-holders are guaranteed exclusive rights to sell a new dr-ug before a generic version can hit the market and undercut profits. These exclusive rights could last for years.
That’s Great. But How Can an Average Joe Know Which Company to Research?
One easy way is to pay attention to what some of the world’s most recognized hedge funds are buying, especially during these times of economic uncertainty.
Blackrock Inc., with over $9 trillion in assets under management, The Vanguard Group, with over $7 trillion in assets under management, and Morgan Stanley, with over $4 trillion in assets under management, have ALL added significant exposure with this same company.
It sure seems like they like what they see in a $264 million market cap biotech innovator called MyMD Pharmaceuticals (NASDAQ: MYMD).
That said, let’s see what makes MyMD Pharmaceuticals tick.
Reason #2: The Company’s MYMD-1 Could Monopolize the Growing $42.1 Billion TNF Dr-ug Market – and That’s HUGE.
The most vexing problem in medicine is when the body attacks itself. This is commonly known as an autoimmune disorder. And science has not fully figured out why it occurs.
Therefore most autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and Type 1 diabetes mellitus are treated by alleviating the symptoms rather than addressing the underlying causes with TNF Alpha dr-ugs.
The worst part? TNF Alpha dr-ugs come with some nasty side effects.
You see, TNF inhibitors lower your immune system to help stop inflammation. This makes it harder to fight off infections. So there is a higher risk for getting colds, flu, urinary tract infections, or even tuberculosis (TB).
According to the National Institutes of Health, up to 23.5 million Americans (more than seven percent of the population) suffer from an autoimmune disease—and that number is quickly rising.
In fact, the global TNF inhibitor dr-ugs market size is anticipated to reach a whopping $42.1 billion by 2026.
What happens if a dr-ug comes to market that can make the competitors obsolete?
Well, it’s here, it’s called MYMD-1, and it’s well into Phase 2 trials after blazing past Phase 1. MYMD-1 actually stops the underlying causes of autoimmune disorders unlike anything seen in the market today.
It’s the real deal. Not to mention, it’s even shown great promise in treating CO-V-ID-19.
Approvals Can Happen Faster Than One Might Think.
MYMD-1 has the potential to gain rapid approval through a special emergency program created by the FDA to move new treatments into the clinic as quickly as possible.
See How MYMD-1 Works Its Magic:
Oh, and let’s not forget – MYMD-1 has also been peer-reviewed.
Reason #3: MyMD Pharmaceuticals (NASDAQ: MYMD) Synthetic Supera-CB Could Catapult Them as a Major Player in the Potential $1.1 Trillion CB Market
Opioid overdose is a national health crisis. In 2019, 50,000 people died from overdosing on opioids, which is 137 deaths per day. This is unacceptable.
This plague is so widespread that the Opioid Use Disorders (OUD) market size was valued at $2.52 billion in 2020 and grew at a compound rate of 8.7%!
But here’s the crazy part. All currently FDA-approved dr-ugs for OUD are opioid agonists or antagonists. So the addiction is being treated with the very same dr-ug causing the addiction.
Supera-CB Is Poised to Help Stop the Madness
MyMD Pharmaceuticals (NASDAQ: MYMD) Supera-CB is a non-opioid option. It is a synthetic CB (patented new molecular entity) being developed as a pharmaceutical dr-ug to address pain, anxiety, sleep disorders, and seizures.
Pre-clinical studies have demonstrated the ability of Supera-CB to inhibit CB2 receptors, comparing it side-by-side with plant-based CB.
And this is really exciting. Preliminary studies show Supera-CB is potentially 7-8 times more effective than Epidiolex or plant-derived CB in reducing MAO-A and MAO-B. This is huge because they play a role in substance addiction in a dose-dependent manner.
Check-Out What Supera-CB Is All About:
Biotech companies with this much potential are the most loved on Wall Street. So it’s easy to understand why such giants Blackrock, Vanguard, and Morgan Stanley have their money on MyMD Pharmaceuticals (NASDAQ: MYMD).
These guys think BIG and play BIG.
And here’s something really interesting. A very similar biotech stock on the London Market exists called Bioventix PLC. It has a $205 million market cap, a tad less than MYMD.
What do you think the stock trades for? How about an astonishing $3,950 per share!
With MYMD trading at about $7.25 as of Oct. 6, 2021, that would provide it a head-spinning potential move of over 54,000% to those heights. You never know, right?
Reason #4: Bullish Trend, Positive Technical Indicators & A Flawless Balance Sheet
Generally, whether one should consider trending stocks should be determined on a case-by-case basis. Every company is different, and research is critical on whether a stock is expected to move higher in the future.
Higher Highs and Higher Lows Point to a Bullish Trend
In the case of MyMD Pharmaceuticals (NASDAQ: MYMD) the chart shows a current bullish trend since May 2021. After touching a May 17, 2021 low of $3.30, it popped as much as 153% to its Sep 22, 2021 high of $8.35, for instance. As you can see in the chart below, MYMD has settled a bit. Yet, since May, it has been making higher highs and higher lows, which could be considered very bullish signs.
Technically Good Looking
While there is no magic bullet system to tell the future price, technical indicators can be useful. These tools are also essential when designing your own trading algorithms and often work well when combined with fundamental analysis and the goals at hand.
According to investing.com on Oct. 5th, 2021, MYMD is looking pretty solid on the weekly moving averages and technical indicators.
Flawless Balance Sheet
When evaluating a biotech stock in the development and approvals process, the company must have enough capital reserves to make it through the next four quarters.
The target company ideally should be in a strong financial position. Fortunately, MyMD Pharmaceuticals looks phenomenal and then some.
For one, the company’s short-term assets exceed both its short- and long-term liabilities.
Plus, MyMD Pharmaceuticals (NASDAQ: MYMD) has enough free cash flow to last them for more than one year.
Reason #5: Two Treatments That Could Become INSANELY VALUABLE
Since no effective therapies get to the root cause of autoimmune disorders, let’s assume that if MYMD-1 succeeds, it could possibly capture up to 25% of the market. The future gross revenue for MYMD-1 could be as much as $10 BILLION.
Should Supera-CB unlock its true potential as a source of therapeutic targets, it could get even crazier. Remember the 2020 market valuation for Opioid Use Disorders (OUD) was $2.52 billion? That could add enough potential to more than DOUBLE the company’s current market cap in just one year.
Nobody Wants to Miss Out on a Historic Breakthrough
Take a look at what MyMD Pharmaceuticals (NASDAQ: MYMD) has in the pipeline. Impressive, right? Even if just one of these therapies hits the market, the results could be legendary.
In short, MyMD Pharmaceuticals (NASDAQ: MYMD) could be positioned to turn the entire pharmaceutical industry on its head as one of the greatest growth stories of our lifetimes.
Watch The Company’s Latest Investor Presentation:
This website / media webpage is owned, operated and edited by TD Media LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 09/23/2021 and ending on 09/23/2021 to publicly disseminate information about (MYMD:US) via digital communications. We have been paid five thousand dollars USD via bank wire transfer.
Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 10/08/2021 and ending on 10/13/2021 to publicly disseminate information about (MYMD:US) via digital communications. We have been paid an additional sixty thousand dollars USD via bank wire transfer. We own zero shares of (MYMD:US). To date we have been paid sixty five thousand dollars USD via bank wire transfer. To disseminate information about (MYMD:US) via digital communications.
(Last updated: 1635113760 unix)